Therapy Areas: Hereditary Disorders
7 January 2019 - - US-based biotechnology companies Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and Arbor Biotechnologies have entered into a strategic research collaboration focused on the discovery o...
21 December 2018 - - US-based biotechnology company Vertex Pharmaceuticals (Europe) Ltd., following constructive discussions with the Scottish government, it will submit Orkambi (lumacaftor/ivacaftor)...
12 December 2018 - - Colistimethate sodium powder for nebulizer solution, delivered by the I-neb AAD system obtained QIDP and "Fast Track" designation by the FDA&nbs...
28 November 2018 - - Treatment with the triple combination of the next-generation corrector VX-659, tezacaftor and ivacaftor resulted in statistically significant improvements in lung function (percen...
20 November 2018 - - The European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion for Orkambi (lumacaftor/ivacaftor) for the treatment of people with ...
5 November 2018 - United Kingdom-based Verona Pharma has completed patient enrolment for a phase two trial for its nebulised RPL554 as an add-on to dual therapy using long-acting anti-muscarinic/long-...
Related Headlines